Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab, receiving his treatment via an intravenous drip once every four weeks at a trial centre in Guildford. Despite undergoing regular MRI and PET scans, he experienced no side effects.